Examination of the efficacy of anamorelin in chemotherapy for gastric cancer patients with cachexia
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000046056
- Lead Sponsor
- Tokyo Metropolitan Tama Medical Center Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Not provided
1. Patients with gastrointestinal disorders who have difficulty in taking food orally or who require gastrointestinal rest 2. Patients with congestive heart failure, underlying heart disease (valvular disease, cardiomyopathy, etc.), history of myocardial infarction or angina, conduction system disorder, risk of QT interval prolongation or a history thereof 3. Patients with a history of administration of anthracyclines 4. Patients receiving strong CYP3A4 inhibitors (drugs containing clarislomycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir, cobicistat) 5. Patients who have confirmed ascites in an amount exceeding the physiological range 6. Patients with confirmed pleural effusion 7. Patients with moderate or higher liver dysfunction (Child-Pugh classifications B and C) 8. Patients judged by the attending physician to be inappropriate for participation in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body weight change rate 12 weeks after anamorelin administration
- Secondary Outcome Measures
Name Time Method